HIV product sales growth driven by Biktarvy and Descovy
HIV product sales rose 12% in Q2 FY2026, with Biktarvy up 7% and Descovy up 48%, primarily due to higher demand and average realized prices.
At the archive date, GILEAD SCIENCES, INC. was expected to release its Q3 2026 10-Q filing on October 28, 2026. Last quarter: Gilead reported a net loss of $10.5 billion in Q2 FY2026 due to $12.9 billion in one-time charges, overshadowing 10% revenue growth from HIV and oncology products.
EPS Estimate
$2.19
Revenue Estimate
$7.94B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the GILD page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
HIV product sales rose 12% in Q2 FY2026, with Biktarvy up 7% and Descovy up 48%, primarily due to higher demand and average realized prices.
Acquired IPR&D expenses totaled $11.2 billion, mainly from the acquisitions of Arcellx ($7.0B), Tubulis ($3.1B), and Ouro Medicines ($1.0B net).
A $1.75 billion impairment was recorded for the Trodelvy non-small cell lung cancer (NSCLC) IPR&D asset following discontinuation of the Phase 3 EVOKE-03 study.
Revenue
$7.8B
+10.18% YoY
EPS (Diluted)
-$8.45
-641.67% YoY
Operating Income
-$10.39B
-520.13% YoY
Add GILD to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.